Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Payables: 2020-2025

Historic Payables for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $879,000.

  • Mereo BioPharma Group's Payables fell 87.96% to $879,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 46.98%. This contributed to the annual value of $8.0 million for FY2024, which is 239.94% up from last year.
  • Mereo BioPharma Group's Payables amounted to $879,000 in Q3 2025, which was down 22.76% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Payables ranged from a high of $16.8 million in Q4 2022 and a low of $879,000 during Q3 2025.
  • Over the past 3 years, Mereo BioPharma Group's median Payables value was $5.0 million (recorded in 2024), while the average stood at $4.7 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Payables surged by 399.25% in 2022, and later plummeted by 87.96% in 2025.
  • Quarterly analysis of 5 years shows Mereo BioPharma Group's Payables stood at $3.4 million in 2021, then skyrocketed by 399.25% to $16.8 million in 2022, then crashed by 86.05% to $2.3 million in 2023, then soared by 239.94% to $8.0 million in 2024, then plummeted by 87.96% to $879,000 in 2025.
  • Its Payables stands at $879,000 for Q3 2025, versus $1.1 million for Q2 2025 and $2.9 million for Q1 2025.